Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 3, 2011, Pages 733-741

  Doi, T ^a   Murakami, H ^b   Ohtsu, A ^a   Fuse, N ^a   Yoshino, T ^a   Yamamoto, N ^b   Boku, N ^b   Onozawa, Y ^b   Hsu, C P ^c   Gorski, K S ^c   Friberg, G ^c   Kawaguchi, T ^d   Sasaki, T ^d  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c AMGEN INC   (United States)

^d Takeda Bio Development Center Ltd   (Japan)

Author keywords

Advanced solid tumors; Conatumumab; Pharmacokinetics; Phase 1 study

Indexed keywords

CONATUMUMAB; DEATH RECEPTOR 5; MONOCLONAL ANTIBODY;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CHILL; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; MONOCYTE; MONOTHERAPY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; JAPAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MONOCYTES; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 80052247459     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1544-1     Document Type: Article

References (31)

1. RM Pitti SA Marsters S Rupper, et al. 1996 Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family J Biol Chem 271 12687 12690 8663110 10.1074/jbc.271.22.12687 1:CAS:528: DyaK28XjtlGjtrc%3D
2. SR Wiley K Schooley PJ Smolak, et al. 1995 Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 673 682 8777713 10.1016/1074-7613(95)90057-8 1:CAS:528: DyaK28XhtF2iug%3D%3D
3. S Kelly A Ashkenazi 2004 Targeting death receptors in cancer with Apo2L/TRAIL Curr Opin Pharmacol 4 333 339 10.1016/j.coph.2004.02.006
4. SW Fesik 2005 Promoting apoptosis as a strategy for cancer drug discovery Nat Rev Can 5 876 885 10.1038/nrc1736 1:CAS:528:DC%2BD2MXht1Witb7J
5. LC DeRosier SM Vickers KR Zinn, et al. 2007 TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotropic pancreatic tumor growth Mol Cancer Ther 6 12 pt1 3198 3207 18089714 10.1158/1535-7163.MCT-07-0299 1:CAS:528:DC%2BD2sXhsVCjsr3I
6. LC DeRosier ZQ Huang JC Sellers, et al. 2006 Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo J Gastrointest Surg 10 1291 1300 17114015 10.1016/j.gassur.2006.08.007
7. SM Ibrahim J Ringel C Schmidt, et al. 2001 Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death Pancreas 23 72 79 11451151 10.1097/00006676-200107000-00011 1:STN:280:DC%2BD38%2FitVCrtg%3D%3D
8. ZW Xu J Kleeff H Friess, et al. 2003 Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells Anticancer Res 23 251 258 12680221 1:CAS:528:DC%2BD3sXislaqtrY%3D
9. BL Hylander R Pitoniak RB Penetrante, et al. 2005 The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice J Transl Med 3 22 15943879 10.1186/1479-5876-3-22
10. P LoRusso D Hong E Heath, et al. 2007 First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors ASCO Meeting Abstracts 25 3534
11. A Ashkenazi 2002 Targeting death and decoy receptors of the tumor-necrosis factor superfamily Nat Rev Cancer 2 6 420 430 12189384 10.1038/nrc821 1:CAS:528:DC%2BD38Xksl2ltr4%3D
12. RW Johnstone AJ Frew MJ Smyth, et al. 2008 The TRAIL apoptotic pathway in cancer onset, progression and therapy Nat Rev Cancer 8 782 798 18813321 10.1038/nrc2465 1:CAS:528:DC%2BD1cXhtFCrtbrM
13. A Ashkenazi RC Pai S Fong, et al. 1999 Safety and antitumor activity of recombinant soluble Apo2 ligand J Clin Invest 104 155 162 10411544 10.1172/JCI6926 1:CAS:528:DyaK1MXkslSmsbw%3D
14. P Kaplan-Lefko T Bush B Belmontes, et al. 2008 AMG 655, a fully human agonistic antibody against death receptor 5, enhances the anti-tumor activity of gemcitabine in MiaPaCa2/T2, a pancreatic cancer model AACR Meeting Abstracts 49 3999
15. G Calogiuri MT Ventura L Mason, et al. 2008 Hypersensitivity to last generation chimeric, umanized and human recombinant monoclonal antibodies for therapeutic use Curr Pharmaceutical Design 14 2883 2891 10.2174/ 138161208786369786 1:CAS:528:DC%2BD1cXhsVKgu7bE
16. D Camidge RS Herbst M Gordon, et al. 2007 A phase I safety and pharmacokinetic study of Apomab, a human DR5 agonist antibody, in patients with advanced cancer ASCO Meeting Abstracts 25 3582
17. AW Tolcher M Mita NJ Meropol, et al. 2007 Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1 J Clin Oncol 25 1390 1395 17416859 10.1200/JCO.2006.08.8898 1:CAS:528:DC%2BD2sXlt1Ghurg%3D
18. R Plummer G Attard S Pacey, et al. 2007 Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers Clin Cancer Res 13 6187 6194 17947486 10.1158/1078-0432.CCR-07-0950 1:CAS:528:DC%2BD2sXhtFygsL%2FK
19. A Patnaik H Wakelee M Mita, et al. 2006 HGS-ETR2-A fully human monoclonal antibody to TRAIL-R2: results of a phase I trial in patients with advanced solid tumors ASCO Meeting Abstracts 24 3012
20. ED Lobo RJ Hansen JP Balthasar 2004 Antibody pharmacokinetics and pharmacodynamics J Pharmaceut Sci 93 2645 2668 10.1002/jps.20178 1:CAS:528:DC%2BD2cXpvV2isLk%3D
21. TS Griffith SR Wiley MZ Kubin, et al. 1999 Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL J Exp Med 189 1343 1353 10209050 10.1084/jem.189.8.1343 1:CAS:528:DyaK1MXisF2hs78%3D
22. B Washburn MA Weigand A Grosse-Wilds, et al. 2003 TNF related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus J Immunol 170 1814 1821 12574346 1:CAS:528:DC%2BD3sXht12itLg%3D
23. Y Hayakawa V Screpanti H Yagita, et al. 2004 NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy J Immunol 172 123 129 14688317 1:CAS:528:DC%2BD3sXpvFeht7w%3D
24. NS Wilson V Dixit A Ashkenzi, et al. 2009 Death receptor signal transducers: nodes of coordination in immune signaling networks Nat Immunology 10 4 348 355 10.1038/ni.1714 1:CAS:528:DC%2BD1MXjtlymsLw%3D
25. JP Sheridan SA Marsters RM Pitti, et al. 1997 Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors Science 277 818 821 9242611 10.1126/science.277.5327.818 1:CAS:528:DyaK2sXlt1eks78%3D
26. H Walczak RE Miller K Ariail, et al. 1999 Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat Med 5 2 157 163 9930862 10.1038/5517 1:CAS:528:DyaK1MXntlSrug%3D%3D
27. IF Pollack M Eriff A Ashkenazi 2001 Direct stimulation of apoptotic signaling by soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells Clin Cancer Res 7 1362 1369 11350907 1:CAS:528:DC%2BD3MXktlels78%3D
28. SE Lamhamedi-Cherradi SJ Zheng KA Maguschak, et al. 2003 Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice Nat Immunol 4 255 260 12577054 10.1038/ni894 1:CAS:528:DC%2BD3sXhsVGitr8%3D
29. E Cretney K Takeda H Yagita, et al. 2002 Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice J Immunol 168 1356 1361 11801676 1:CAS:528: DC%2BD38XpsFektw%3D%3D
30. GE Diehl HH Yue K Hsieh, et al. 2004 TRAIL-R as a negative regulator of innate immune cell responses Immunity 21 877 889 15589175 10.1016/j.immuni.2004. 11.008 1:CAS:528:DC%2BD2MXjvFGjuw%3D%3D
31. Pan Y, Xu R, Peach M, et al (2007) Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors. ASCO Meeting Abstracts, 3535